Efficacy and Outcome of Tixagevimab-Cilgavimab Prophylaxis Administration in Kidney Transplant Patients

iBackground:/i Kidney transplant recipients are immunocompromised and at high risk of developing COVID-19. Tixagevimab/cilgavimab has been shown to reduce the risk of COVID-19 in immunocompromised individuals. However, information regarding the safety and efficacy of tixagevimab/cilgavimab use in kidney transplant recipients remains limited. Therefore, in this study, we aimed to evaluate the efficacy and safety of tixagevimab/cilgavimab in individuals who have undergone kidney transplantation. iMethods:/i A retrospective, single-center study was conducted on all patients who underwent kidney transplantation between June 2022 and January 2023. The recipients were divided into treatment and control groups based on tixagevimab/cilgavimab therapy status. The incidence of COVID-19, acute rejection, hypersensitivity reactions, and cardiac events was compared between the groups. iResults:/i A total of 93 patients were included in the study, of whom 38 received tixagevimab/cilgavimab. Prior to drug administration, 38 patients (40.9%) were infected with COVID-19; of these, 12 (31.6%) required hospitalization and two (5.2%) required admission to the intensive care unit (ICU). During the post-administration period, seven patients (7.5%) developed COVID-19; of these patients, four (57%) received tixagevimab/cilgavimab, and three (43%) did not. None of the patients required hospitalization or ICU admission. iConclusion:/i The incidence of COVID-19 was similar across study groups. However, the severity of the infection appeared to be milder in patients who received tixagevimab/cilgavimab.